Antimicrobial Activity of Doripenem Tested Against Leading Bacterial Pathogens: Results from a Latin American Surveillance Study (2003-2006)

Página do item simplificado
dc.contributor.authorGales, Ana Cristina [UNIFESP]
dc.contributor.authorJones, Ronald N.
dc.contributor.authorSader, Helio Silva [UNIFESP]
dc.contributor.authorFritsche, Thomas R.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionJMI Labs
dc.date.accessioned2018-06-15T14:04:34Z
dc.date.available2018-06-15T14:04:34Z
dc.date.issued2008-10-01
dc.description.abstractCarbapenems have been the therapeutic choice for empirical treatment of serious infections when multidrug-resistant Gram-negative organisms are suspected. Doripenem is a parenteral 1-beta-methyl-carbapenem that was recently approved in the USA for complicated urinary tract and intra-abdominal infections. We performed a longitudinal surveillance study on the in vitro activity of doripenem and comparator agents against patient isolates from Latin America. Consecutive, non-duplicate bacterial isolates (13,809) were collected from patients in 10 medical centers in Brazil (45.2%), Chile (21.1%), Argentina (17.9%), Mexico (12.9%) and Venezuela (2.9%). Isolate identifications were confirmed and susceptibility testing was performed using reference methods at a central laboratory (JMI Laboratories, North Liberty, IA). Doripenem and meropenem were the most active compounds tested against E. coli and Klebsiella spp. (MIC(90) values, <= 0.12 mu g/mL), including against those strains with ESBL phenotypes (15.2% of E. coli and 44.9% of Klebsiella spp.). All Enterobacter spp. strains were inhibited at <= 4 mu g/mL of doripenem, meropenem or imipenem; only ertapenem was less active (94.8% susceptible). Furthermore, only 86.6 and 77.0% of Enterobacter spp. strains were susceptible to amikacin and polymyxin B, respectively. Doripenem and meropenem were equally potent against R aeruginosa (MIC(50) 1 mu g/mL) and Acinetobacter spp. (MIC(50) 2 mu g/mL); however, doripenem inhibited a greater number of R aeruginosa (78.1%) at MIC values of <= 4 mu g/mL compared to meropenem (70.9%) or imipenem (67.9%). Moreover, doripenem inhibited 34.0% of imipenem-non-susceptible P aertiginosa isolates at MIC values <= 4 mu g/mL. Doripenem inhibited all oxacillin-susceptible staphylococci and S. pneumoniae, including penicillin-resistant strains, at <= 2 mu g/mL. In summary, doripenem showed potent activity against Enterobacteriaceae (including ESBL- and/or AmpC-producing strains), oxacillin-susceptible staphylococci and streptococci isolated in Latin American hospitals participating in the international doripenem surveillance program. Doripenem activity was also comparable to that of other carbapenems against P aeruginosa and Acinetobacter spp. Given limited therapeutic choices available, doripenem shows a promising broad-spectrum that should prove useful in geographic regions with problematic emerging resistances.en
dc.description.affiliationUniv Fed Sao Paulo, ALERTA Lab, Div Infect Dis, UNIFESP, BR-04023900 Sao Paulo, Brazil
dc.description.affiliationJMI Labs, N Liberty, IA USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, ALERTA Lab, Div Infect Dis, UNIFESP, BR-04023900 Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent59-66
dc.identifier.citationBrazilian Journal Of Infectious Diseases. Salvador: Contexto, v. 12, p. 59-66, 2008.
dc.identifier.issn1413-8670
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/42886
dc.identifier.wosWOS:000266634000008
dc.language.isoeng
dc.publisherContexto
dc.relation.ispartofBrazilian Journal Of Infectious Diseases
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCarbapenemen
dc.subjectantimicrobial resistanceen
dc.subjectnosocomial infectionsen
dc.subjectESBLen
dc.titleAntimicrobial Activity of Doripenem Tested Against Leading Bacterial Pathogens: Results from a Latin American Surveillance Study (2003-2006)en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos